Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 7/20 | 0.53 |
| ▸ | BLM | P54132 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | EDNRA | P25101 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | HBB | P68871 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | VCP | P55072 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | HPRT1 | P00492 | 3/20 | 0.49 |
| ▸ | POLG | P54098 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13528364 | 0.90 | PNP (0.52) | PNPBLMUSP2TSHREDNRA | |
| SCHEMBL29503314 | 0.88 | PNP (0.56) | PNPBLMUSP2TSHREDNRA | |
| SCHEMBL18744083 | 0.84 | PNP (0.54) | PNPBLMUSP2TSHREDNRA | |
| SCHEMBL10402774 | 0.79 | PNP (0.57) | PNPBLMUSP2TSHREDNRA | |
| SCHEMBL7614528 | 0.76 | PNP (0.58) | PNPBLMUSP2TSHREDNRA | |
| SCHEMBL18059144 | 0.74 | PNP (0.50) | PNPBLMUSP2TSHREDNRA | |
| SCHEMBL14121679 | 0.74 | PNP (0.54) | PNPBLMUSP2TSHREDNRA | |
| SCHEMBL14137223 | 0.74 | PNP (0.51) | PNPBLMUSP2TSHREDNRA | |
| SCHEMBL14125281 | 0.73 | PNP (0.50) | PNPBLMUSP2TSHREDNRA | |
| SCHEMBL10496676 | 0.73 | TK1 (0.56) | PNPBLMUSP2TSHREDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170239279-A1 | PHOSPHONATE COMPOUNDS | UNIV CALIFORNIA (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170239279-A1 | PHOSPHONATE COMPOUNDS | UNIV CALIFORNIA (US) | 2017-08-24 | — | — | US | disclosed |
| US-9649321-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-05-16 | — | — | US | disclosed |
| US-9649321-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160067268-A1 | PHOSPHONATE COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-10 | — | — | US | disclosed |
| US-20160067268-A1 | PHOSPHONATE COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-10 | — | — | US | disclosed |
| US-9206208-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206208-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150141375-A1 | Methods of Treating Viral Associated Diseases | CHIMERIX, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20150141375-A1 | Methods of Treating Viral Associated Diseases | CHIMERIX, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20100173870-A1 | Phosphonate Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-07-08 | — | — | US | disclosed |
| US-20100173870-A1 | Phosphonate Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-07-08 | — | — | US | disclosed |
| US-7687480-B2 | Alkylpropanediol derivatized adefovir; reduced toxicity; osteoporosis, bone metabolism disorders , cancer, viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687480-B2 | Alkylpropanediol derivatized adefovir; reduced toxicity; osteoporosis, bone metabolism disorders , cancer, viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-03-30 | — | — | US | disclosed |
| US-7452898-B2 | Use of 1-O-octadecylpropanediol-3-cidofovir to treat viral diseases such as HIV, influenza, herpes virus, cytomegalovirus, hepatitis virus, Epstein-Barr virus, varicella zoster virus, orthopox virus, ebola virus and papilloma virus | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452898-B2 | Use of 1-O-octadecylpropanediol-3-cidofovir to treat viral diseases such as HIV, influenza, herpes virus, cytomegalovirus, hepatitis virus, Epstein-Barr virus, varicella zoster virus, orthopox virus, ebola virus and papilloma virus | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-11-18 | — | — | US | disclosed |
| US-20080103115-A1 | Alkylpropanediol derivatized adefovir; reduced toxicity; osteoporosis, bone metabolism disorders , cancer, viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-05-01 | — | — | US | disclosed |
| US-20080103115-A1 | Alkylpropanediol derivatized adefovir; reduced toxicity; osteoporosis, bone metabolism disorders , cancer, viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-05-01 | — | — | US | disclosed |
| US-20070161602-A1 | New phosphonate ester derivatives of purine or pyrimidine antivirals; side effect reduction, less toxic, bioavailability | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2007-07-12 | — | — | US | disclosed |
| US-20070161602-A1 | New phosphonate ester derivatives of purine or pyrimidine antivirals; side effect reduction, less toxic, bioavailability | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103115-A1 | Alkylpropanediol derivatized adefovir; reduced toxicity; osteoporosis, bone metabolism disorders , cancer, viral infections | APRT, AASDHPPT, APOBEC3G | PNP 11/4885BLM 1573/4885USP2 3661/4885 |
| US-20170239279-A1 | PHOSPHONATE COMPOUNDS | PHPT1, PHOSPHO1, PIK3CA | PNP 74/4885BLM 3431/4885USP2 4514/4885 |
| US-20160067268-A1 | PHOSPHONATE COMPOUNDS | PHPT1, PHOSPHO1, PIK3CA | PNP 74/4885BLM 3431/4885USP2 4514/4885 |
| US-20070161602-A1 | New phosphonate ester derivatives of purine or pyrimidine antivirals; side effect reduction, less toxic, bioavailability | PNP, TYMP, UMPS | PNP 1/4885BLM 1423/4885USP2 4053/4885 |
| US-20150141375-A1 | Methods of Treating Viral Associated Diseases | HAVCR2, EIF2AK2, TSLP | PNP 727/4885BLM 2664/4885USP2 2610/4885 |
| US-20100173870-A1 | Phosphonate Compounds | PHPT1, PHOSPHO1, PIK3CA | PNP 74/4885BLM 3431/4885USP2 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.